Nebenwirkungen · Gobivaz
GOBIVAZ 100 mg solution for injection in pre-filled pen. · Abschnitt 4.8 · PDF-Seite 102
HOS-153600 · Präparat HOS-101000
Malignancies Lymphoma The incidence of lymphoma in golimumab-treated patients during the pivotal trials was higher than expected in the general population. In the controlled and uncontrolled portions of these trials with a median follow-up of up to 3 years, a greater incidence of lymphoma was observed in patients receiving golimumab 100 mg compared with patients receiving golimumab 50 mg. Lymphoma was diagnosed in 11 subjects (1 in the golimumab 50 mg treatment groups and 10 in the golimumab 100 mg treatment groups) with an incidence (95% CI) per 100 subject-years of follow-up of 0.03 (0.00, 0.15) and 0.13 (0.06, 0.24) events for golimumab 50 mg and 100 mg respectively and 0.00 (0.00, 0.57) events for the placebo. The majority of lymphomas occurred in study GO-AFTER, which enrolled patients previously exposed to anti-TNF agents who had longer disease duration and more refractory disease (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T10:38:00Z · SHA-256 b368a4f3ae6dce5887430617ccfcdc36900996af800ff08514415b29e19f2102 · Passage b320eb0437fed037bb6e27aa4a550bed3e39f1811a9a00ba1afb3f134f4f6e59 · Zeichen 9988–10906 im Abschnitt